Table 1.

Demographics and baseline characteristics (n = 41)

Demographic or characteristic	Data
Sex
Male	25 (61.0)
Female	16 (39.0)
Age, median (range), y	62.0 (28-75)
Age ≥ 65 y	13 (31.7)
ECOG PS
0	10 (24.4)
1	27 (65.9)
2	4 (9.8)
Disease status at study entry
Relapsed	30 (73.2)
Refractory	11 (26.8)
Stage at study entry for non-GCB type DLBCL
I	6 (14.6)
II	4 (9.8)
III	10 (24.4)
IV	21 (51.2)
IPI at study entry
Low	5 (12.2)
Low-intermediate	16 (39.0)
High-intermediate	17 (41.5)
High	3 (7.3)
Bulky disease (any target lesion LDi > 7.5 cm)	6 (14.6)
Baseline bone marrow involvement	4 (9.8)
Extranodal disease at study entry	23 (56.1)
Elevated LDH at baseline	32 (78.0)
Prior lines of therapy, median (range)	2 (1-6)

Unless otherwise noted, data are n (%).

LDH, lactate dehydrogenase; LDi, longest diameter of a lesion.